The research from CCS underscores the importance of ensuring that patients access continuous glucose monitoring (CGM) devices through their medical benefits instead of pharmacy benefits. The data-driven insights highlight significant cost savings and improved adherence, which are crucial for both patient outcomes and healthcare sustainability. CCS’s integration of education, coaching, and AI-driven predictive tools further cements its role as a leader in chronic care management, particularly for diabetes care. With rising CGM adoption and an urgent need for effective patient support, CCS’s innovations, like PropheSee™, offer a promising model for the future of proactive chronic care management.

Ginkgo Bioworks Launches Protein LLM and Model API Powered by Google Cloud News Product News Read More Chris-Anne Roque Peer-Reviewed Research Shows CGM Benefits Through Medical Over Pharmacy Clinical News News Read More Chris-Anne Roque Mirador Therapeutics Appoints Gregg Gilbert as CFO to Drive Growth Hiring News News Read More Chris-Anne Roque Entact Bio Appoints Ruben Tommasi, Ph.D., as Chief Scientific Officer Hiring News News Read More Chris-Anne Roque #467 – Dr. Jason Stein, Chief Medical Officer at Ingenious Med AI Healthcare Innovation Read More Windley Mathurin BioDuro-Sundia Appoints Dr. Armin Spura as New CEO Hiring News News Read More Chris-Anne Roque